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 Patient: Female, 30-year-old
 Final Diagnosis: Pseudoangiomatous stromal hyperplasia (PASH)
 Symptoms: Breast mass
 Medication: —
 Clinical Procedure: Lumpectomy
 Specialty: Obstetrics and Gynecology
 Objective: Unknown ethiology
 Background: Pseudoangiomatous stromal hyperplasia (PASH) is an uncommon benign breast lesion.
 Case Report: PASH is reported in a young female in treatment for neurological diseases with multi-drug therapy (clonaze-
pam, valproate and risperidone). Her menstrual cycles are irregular, and she reached menarche very late.
 Conclusions: The higher PASH prevalence in premenopausal woman (the majority of whom are actively taking oral contra-
ceptive pills), in 24% to 47% of men with gynecomastia and during pregnancy supports a hormonal etiology; 
the interaction between clonazepam, valproate, risperidone and progesterone could increase the level of pro-
gesterone that could stimulate PASH growth.
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Background
Pseudoangiomatous stromal hyperplasia (PASH) in an uncom-
mon benign breast lesion that generally presents as a fast-
growing palpable lesion or gynecomastia. PASH etiology is un-
known, but hormonal influences are supposed. Our case report 
deals with a young woman with irregular menstrual cycles, 
delayed menarche and multi-drug therapy, who developed a 
breast lump increasing in volume.
Case Report
A 30-year-old female presented to our hospital with a left breast 
mass in February 2017. Her past medical history included in-
tellectual disability and epilepsy from age of 2, secondary to 
neonatal hypoxia. She was receiving sodium valproate, pheno-
barbital, clonazepam and risperidone. She had no family his-
tory of breast disease or ovarian cancer. Her body weight was 
normal (body mass index 21 kg/m2). She reached menarche 
at 22 years; her parents referred the use of estro-progestinic 
pills before the age of 22 years, unsuccessful in drug-induced 
menstrual flow. At PASH diagnosis, her menstrual cycle was 
irregular with a normal menstrual flow every 40 to 60 days. 
She had no pregnancies in the past.
Physical examination showed a 3 cm fixed and firm lump 
with a not-defined border below left nipple areola complex. 
Ultrasound examination showed a solid, not homogenous le-
sion measuring 20×10 mm in size in left Q3-5 with mild pe-
ripheral vascularization at color-doppler evaluation, irregular 
margins, ductal ectasia, without acoustic shadowing (Figure 1). 
There was likely bilateral reactive axillary lymphadenopathy. 
Fibrous mastopathy signs and fibroadenomas were found in 
both breasts. The ultrasound finding was suspicious for ma-
lignancy. Under ultrasonography guidance, core needle biop-
sy was performed, and histopathologic report showed benign 
fibroepithelial node, enriched in vascular space, suggestive 
for PASH. Considering the breast mass dimension, lumpecto-
my was performed. During surgery, the lump was hardly dis-
sociable from adjacent tissue. The tumor resected from the 
left breast measured 25 mm. She was discharged on day 1 af-
ter surgery. Pathology confirms hamartoma-like fibroepitheli-
al lesion with PASH features. No recurrence of disease is ob-
served at 32 months follow-up.
Discussion
Pseudoangiomatous stromal hyperplasia (PASH) is an uncom-
mon breast benign stromal lesion, first described by Vuitch in 
1986 [1]. Incidental microscopic PASH can be found in up to 
23% of consecutive breast specimens [2]. In contrast, PASH as 
a main pathological finding is a rare entity. Preoperative core 
biopsy fails to diagnose PASH in 35% of cases [3]. Ultrasound 
imaging is not specific: generally, it appears like a hypo-echoic 
ovoidal mass with regular margin. Treatment is usually surgical 
excision, although “watch and wait” strategy can be applied if 
PASH diagnosis is made on core biopsy and if the lump is less 
than 2 cm in size. Rapidly increased lump needs surgical ap-
proach to valuate contextual presence of ductal carcinoma in 
situ (DCIS). Recurrence rate is 9% to 21% [4], probably due to 
the persistence of a residual mass after surgery [5,6]. PASH is 
related to benign and malign breast lesions in up to 23% of 
cases but is not associated with an increased risk for maligni-
ty [7], rather it seems to be protective [8] although 2 case of 
synchronous tumoral PASH in the breast and axillary tissue 
are reported in literature [9,10]. On the other hand, there is 
an increased ipsilateral breast cancer prevalence in patients 
treated for PASH more than 5 years after PASH biopsy [11].
PASH is a complex network of slit-like spaced lined by en-
dothelial-like spindle cells surrounded by dense collagenous 
stroma [12]. Fibroblasts and myofibroblasts proliferation and 
collagen over-secretion create a solid tissue with cystic areas 
resembling ectatic vessels (pseudo vascular spaces).
PASH stromal cells nuclei express high density progesterone 
receptors [13]; estrogen receptors expression is more vari-
able [14]. Normal mammary stroma that showed no proges-
terone receptor staining instead. Progesterone is metabolized 
by cytochrome P450, that is inhibited by clonazepam [15]; val-
proate and risperidone are metabolized by cytochrome P450, 
so it could be a competition for the cytochrome between our 
patient multidrug therapy and progesterone. These inter-
actions could increase the level of progesterone that could 
stimulate PASH growth. A hormonal etiology is also support-
ed by the higher PASH prevalence in premenopausal wom-
an (the majority of whom are actively taking oral contracep-
tive pills) [16], in 24% to 47% of men with gynecomastia [17] 
and by reported case of PASH in a transgender male during 
Figure 1. A lump found during the ultrasound examination.
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hormone therapy [18] or during pregnancy [19]. PASH affects 
pre-menopausal women or menopausal women in hormone 
replacement therapy (HRT). Anti-hormonal therapy could the-
oretically reduce PASH mass: a case report suggests tamoxifen 
use as alternative approach in management of PASH [20,21] 
but the lack of evidence does not support anti-hormonal ther-
apy as adjuvant therapy.
Conclusions
PASH is an uncommon but benign lesion of the breast. Its ori-
gin is still unclear, but it seems to be related to hormone stim-
ulation (primarily progesterone stimulation).
Efforts are necessary to recognized PASH lesion during diag-
nostic examinations (ultrasound, breast core-biopsy) in order 
to consider watch and wait management, procrastinating sur-
gery if not necessary. A multidisciplinary approach is the best 
way to manage breast lesions, including PASH.
Knowledges about risk factor (related to hormonal etiology pre-
viously described) is essential to report suspected PASH lesion 
to the pathologist and help him to distinguish PASH from inva-
sive cancer and support a conservative management if possible.
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